Publicacións nas que colabora con M. LLamas Velasco (14)

2024

  1. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2023

  1. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  2. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  3. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  4. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  5. Ruxolitinib and Squamous Cell Carcinoma

    Actas Dermo-Sifiliograficas

  6. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study

    Dermatologic Therapy

  2. Knowledge and role of dermatologists in life-threatening infections: a national survey among hospital skin specialists

    Journal of the European Academy of Dermatology and Venereology

2021

  1. A new classification of the severity of psoriasis: What’s moderate psoriasis?

    Life, Vol. 11, Núm. 7

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

  3. Obesity — A Risk Factor for Psoriasis and COVID-19

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 6, pp. 489-494

  4. Survey on the impact, current needs and expectations of spanish patients with psoriasis. NEXT survey

    Piel, Vol. 36, Núm. 10, pp. 648-656

2018

  1. IL17RA gene variants and anti-TNF response among psoriasis patients

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 76-80